Buparlisib modulates PD-L1 expression in head and neck squamous cell carcinoma cell lines
- 1 November 2020
- journal article
- research article
- Published by Elsevier in Experimental Cell Research
- Vol. 396 (1) , 112259
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Forschungsgemeinschaft (BA3696/7-1)
This publication has 32 references indexed in Scilit:
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer ProgressionCell, 2015
- Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell linesInvestigational New Drugs, 2015
- Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeuticsJournal of Hematology & Oncology, 2013
- PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck CancerClinical Cancer Research, 2013
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K InhibitionClinical Cancer Research, 2013
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase InhibitorMolecular Cancer Therapeutics, 2012
- Radiation-induced cell signaling: inside-out and outside-inMolecular Cancer Therapeutics, 2007
- Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in gliomaNature Medicine, 2006
- Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunityNature Reviews Immunology, 2004
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionNature Medicine, 2002